Actavis eyes $100 million after OxyContin settlement


Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.

To read the rest of this story, register here for free content, or subscribe for access to archive.

If you have already subscribed please login.

If you have any technical issues please email

For access to the complete website, archive, and to receive print publications, choose 'SUBSCRIBER'. For access to the latest news on the website and weekly email news alerts choose the 'FREE' registration. 


actavis, oxycontin, purdue pharma, Fitzpatrick, Cella, Harper & Scinto